The D225G change in 2009 H1N1 influenza virus

by Vincent Racaniello on 18 March 2010

sialic-acid-2Last year a mutation in the HA gene of the 2009 H1N1 influenza virus was identified in isolates from patients with severe disease. At the time I concluded that the emergence of this change was not a concern. Recently the Norwegian Institute of Public Health reported that the mutation, which causes a change from the amino acid aspartic acid to glycine at position 225 of the viral HA protein (D225G), has been identified in 11 of 61 cases (18%) of severe or fatal influenza, but not in any of 205 mild cases. Have these observations changed my view of the importance of this mutation?

The cell receptor for influenza A virus strains is sialic acid. Human influenza A strains bind preferentially to sialic acids linked to galactose by an alpha(2,6) bond, while avian and equine strains prefer alpha(2,3) linked sialic acids (pictured). Alpha(2,6) linked sialic acids are dominant on epithelial cells in the human nasal mucosa, paranasal sinuses, pharynx, trachea, and bronchi. Alpha(2,3) linked sialic acids are found on nonciliated bronchiolar cells at the junction between the respiratory bronchiole and alveolus, and on type II cells lining the alveolar wall.

The 2009 swine-origin H1N1 influenza virus is known to bind both alpha(2,3) and alpha(2,6) linked sialic acids. This is consistent with the ability of the virus to cause lower respiratory tract disease. The D225G change might be expected to increase affinity for alpha(2,3) linked sialic acids. However, it is not known if increased binding affinity correlates with higher infectivity and pathogenicity. It’s equally likely that high affinity binding might restrict the movement of the virus in lung tissues by causing retention of the virus on nonsusceptible cells.

One view of the D225G mutation is that it is spreading globally and causing more severe disease. However there is no evidence in support of this hypothesis. According to WHO, viruses with the D225G change have been found in 20 countries since April 2009, but there has been no temporal or geographic clustering. As of January, the HA change has been identified in 52 sequences out of more than 2700. Furthermore, the authors of the Norwegian study write, “Our observations are consistent with an epidemiological pattern where the D225G substitution is absent or infrequent in circulating viruses, with the mutation arising sporadically in single cases where it may have contributed to severity of infection”.

One explanation for the sporadic emergence of influenza viruses with the D225G change is that they are selected for in the lower respiratory tract where alpha(2,3) sialic acids are more abundant than in the upper tract. Such selection might be facilitated in individuals with compromised lung function (e.g. asthmatics, smokers) or suboptimal immune responses, in whom the virus more readily reaches the lung. One way to address this hypothesis would be to compare the HA at amino acid 225 of viral isolates obtained early in infection, from the upper tract, with isolates obtained from the lower tract late in disease. However such paired isolates have not yet been obtained. But whether the presence of viruses with D225G increases viral virulence is unknown. Many H1N1 isolates from cases of fatal or severe disease do not contain this amino acid change.

There is an alternative explanation for the isolation of at least some influenza viruses with the D225G change: it is selected by propagation in embryonated chicken eggs. This selection occurs because cells of the allantoic cavity of chicken eggs have only alpha(2,3) linked sialic acids. A change in receptor specificity does not occur when viruses are propagated in MDCK (canine kidney) cells, which possess sialic acids with both alpha(2,3) and alpha(2,6) linkages. Consistent with this hypothesis, WHO reports (pdf) that the D225G substitution in 14 virus isolates occurred after growth in the laboratory.

Studies on the binding of influenza viruses to glycan arrays have shown that attachment is influenced not only by the linkage to the next sugar, but the type of sialic acid as well as the rest of the carbohydrate chain. The distribution of all the possible sialic acid containing sugars in the respiratory tract is unknown, as is the specific molecules that can support productive viral infection. The view that HA preferentially binds to either alpha(2,3) or alpha(2,6) linked sialic acids is likely to be overly simplistic: another casualty of reductionism.

Kilander A, Rykkvin R, Dudman SG, & Hungnes O (2010). Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A(H1N1) virus and severe clinical outcome, Norway 2009-2010. Euro surveillance : bulletin europeen sur les maladies transmissibles = European communicable disease bulletin, 15 (9) PMID: 20214869

Takemae N, Ruttanapumma R, Parchariyanon S, Yoneyama S, Hayashi T, Hiramatsu H, Sriwilaijaroen N, Uchida Y, Kondo S, Yagi H, Kato K, Suzuki Y, & Saito T (2010). Alterations in receptor-binding properties of swine influenza viruses of the H1 subtype after isolation in embryonated chicken eggs. The Journal of general virology, 91 (Pt 4), 938-48 PMID: 20007353

Garcia-Sastre, A. (2010). Influenza Virus Receptor Specificity. Disease and Transmission American Journal Of Pathology DOI: 10.2353/ajpath.2010.100066

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 1 comment }

Contagion, the movie

by Vincent Racaniello on 16 March 2010

Contagion (2001)Contagion is the name of a new action-thriller movie about a global outbreak of a deadly viral disease. Slated to be released in 2011, it is directed by Steven Soderbergh and stars Matt Damon, Kate Winslet, Jude Law, Marion Cotillard, Gwyneth Paltrow, and Lawrence Fishburne. That’s certainly an outstanding crew, but will they get the science right?

According to Beyond Hollywood, “the film will have most of the big names playing doctors who are called to duty by the Centers for Disease Control when a major viral outbreak starts killing people around the world. The cast will then be split up and jet off to different continents.” Dread Central calls it ‘the deadly viral outbreak film of the decade’. Apparently Jude Law will play “a kind of unbridled blogger who’s a sort of scaremonger. Basically, it’s about a deadly virus unleashed and you see it from many different points of view, whether it be the public, medical care, politicians.”

The particular virus involved in Contagion has not been identified, but I have a good source which tells me that it’s a paramyxovirus. That’s not too hard to believe since the lethal Hendra and Nipah viruses are both members of the same family.

We’ll have to wait for more information to determine if the science in the film is credible. I do know that a prominent virologist, for whom I have a great deal of respect, has been hired as a script consultant. Whether or not the director and writer actually listen to that virologist is another question.

Moviegoers may know about the eponymous 2001 sci-fi movie (pictured) in which a group of terrorists concocted a seemingly unstoppable strain of Ebola. The first target is the President of the United States. Scientific reality just isn’t exciting enough for the movies.

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 9 comments }

TWiV 73: Entering the ends

by Vincent Racaniello on 14 March 2010

Hosts: Vincent Racaniello, Dickson Despommier, and Rich Condit

Vincent, Dickson, and Rich discuss multipotent progenitor bone marrow cells as a reservoir of HIV-1, integration of HHV-6 into telomeres, and dispersal of West Nile virus across the US by mosquitoes.

This episode is sponsored by Data Robotics Inc. Use the promotion code VINCENT to receive $50 off a Drobo or $100 off a Drobo S.

Win a free Drobo S! Contest rules here.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Download TWiV #73 (63 MB .mp3, 87 minutes)

Subscribe to TWiV (free) in iTunes , at the Zune Marketplace, by the RSS feed, or by email.

Links for this episode:

Weekly Science Picks

Dickson Whole-Genome Sequencing in a Patient with Charcot–Marie–Tooth Neuropathy (NEJM and NY Times)
Rich Invisible Frontiers: The Race to Synthesize a Human Gene by Stephen Hall
Vincent Conference on Retroviruses and Opportunistic Infections – videocasts

Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv or leave voicemail at Skype: twivpodcast. You can also post articles that you would like us to discuss at microbeworld.org and tag them with twiv.

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 0 comments }

influenza-rna-2The second RNA segment of some influenza virus strains encodes a protein called PB1-F2 that might contribute to virulence. Speaking about the 2009 pandemic H1N1 strain, Peter Palese noted that “If this virulence marker is necessary for an influenza virus to become highly pathogenic in humans or in chickens, then the current swine virus doesn’t have what it takes to become a major killer.” If the pandemic virus mutated so that the PB1-F2 protein is produced, would it become a killer?

The PB1-F2 protein is not produced in cells infected with the 2009 H1N1 strain because there are three translation stop codons at nucleotide positions 12, 58, and 88.  To determine if this protein plays a role in virulence, the second RNA segment of the A/California/04/2009 H1N1 strain was genetically altered to code for a full-length PB1-F2 protein. When mice or ferrets were infected intranasally with the modified virus, no significant differences in symptoms of infection were observed compared with mice infected with Cal/09 virus. The parameters measured included weight loss, viral replication in the lungs, and lung pathology.

The PB1-F2 protein has been shown to increase the severity of primary viral and secondary bacterial infections in mice. However, no increased mortality was observed in mice co-infected with Streptococcus pneumoniae and Cal/09 virus that can produce PB1-F2 protein.

Some differences were observed that might be attributed to the production of PB1-F2 protein. Synthesis of this protein was associated with enhanced replication in a human respiratory cell line. Furthermore, mice infected with the modified virus produced higher levels of some pro-inflammatory cytokines than mice infected with Cal/09 virus. The significance of these observations is unclear. Higher levels of virus production can influence transmission of infection among hosts, but the effect of PB1-F2 on this property was not examined. While increased proinflammatory cytokines could exacerbate or ameliorate disease, there was no effect on pathogenesis in mice.

The authors conclude that “mutations enabling the production of PB1-F2 in the Cal/09 influenza virus do not have a significant impact on virus virulence in mice or in ferrets.” Whether similar results would be observed in humans is unknown. But not all PB1-F2 proteins are the same: that produced by the genetically altered Cal/09 virus is different from the protein made by the 1918 H1N1 virus. It would be interesting to determine if the nature of the PB1-F2 protein has any effect on the virulence of the 2009 pandemic virus.

Hai, R., Schmolke, M., Varga, Z., Manicassamy, B., Wang, T., Belser, J., Pearce, M., Garcia-Sastre, A., Tumpey, T., & Palese, P. (2010). PB1-F2 expression by the 2009 pandemic H1N1 influenza virus has minimal impact on virulence in animal models Journal of Virology DOI: 10.1128/JVI.02717-09

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 6 comments }

Virology lecture #12: Infection basics

by Vincent Racaniello on 11 March 2010


Download: .wmv (369 MB) | .mp4 (77 MB)

Visit the virology W3310 home page for a complete list of course resources.

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 1 comment }

Trivalent influenza vaccine for the 2010-2011 season

by Vincent Racaniello on 10 March 2010

influenza-vaccineThe World Health Organization and the US Food & Drug Administration have decided on the composition of the influenza virus vaccine that will be used during the 2010-2011 season in the northern hemisphere. The trivalent preparation will contain the following influenza virus strains: A/California/7/2009 (H1N1); A/Perth/16/2009 (H3N2); and B/Brisbane/60/2008. The same trivalent vaccine is also being used to prepare for the upcoming winter in the southern hemisphere.

The A/California/7/2009 (H1N1) virus is the pandemic strain that was used in the 2009 H1N1 monovalent vaccine. That virus has not yet undergone sufficient antigenic drift to warrant selection of a new strain for the vaccine. Note that a seasonal H1N1 strain from previous years will not be included in the vaccine. This change has been made because epidemiological evidence suggests that these viruses will probably not circulate at significant levels during the 2010-2011 northern hemisphere season. Although the vast majority of circulating influenza viruses in humans are related to the 2009 H1N1 pandemic strain, sporadic influenza A(H3N2) activity continues to be reported in several countries. This is the reason why an H3N2 component is part of the vaccine.

The selection of viruses for seasonal flu vaccines is based on which influenza viruses circulate during the previous season. Sample viruses are collected by 130 national influenza centers in 101 countries and data on disease trends are analyzed by the four World Health Organization (WHO) Collaborating Centers for Reference and Research on Influenza. Vaccine viruses are selected which will most likely protect against the main circulating viruses during the next influenza season. WHO makes recommendations about which specific virus strains should be included in the vaccine. Individual countries then decide which viruses will be included in the influenza vaccine.

Even though the 2009 H1N1 strain has not undergone significant antigenic changes, it’s important to be immunized again in anticipation of the next influenza season. That’s because immunity conferred by the vaccine isn’t particularly long lasting. As Adolfo Garcia-Sastre told me today*, even if influenza didn’t change, you would still have to be immunized every year to protect against infection.

*I recorded our conversation. Look for it at TWiV within the next few weeks.

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 5 comments }

Virology study guide

by Vincent Racaniello on 8 March 2010

Hamilton hallToday my virology class is taking a midterm examination. To prepare for this in-class test, I provided the students with a study guide highlighting what I believe to be the main concepts that they should learn from each lecture.  Once all the students have taken the exam, I’ll post it here for everyone else to take. To prepare for that day, you might want to start by reviewing the first half of the course, which covered the infectious cycle.

Virology W3310 is held in Hamilton Hall (image), an original McKim, Mead, and White building.

Lecture 1 – What is a virus?

  • Viruses were originally discovered because of their size, relative to known bacterial cells. Tobacco mosaic virus was called a “filterable infectious agent” by this criterion. Why is size not a good defining feature for viruses? What is a better definition?
  • Are viruses living? Why or why not?
  • What is the three part strategy followed by every virus that makes it distinct from all other forms of self-replicating matter?
  • It is said that viruses violate the cell theory (cells only arise from preexisting cells).  To which phase of a virus life cycle (the single step growth curve) does this statement refer?  What is the explanation for this phase of the growth curve?
  • A viral genome must make mRNA: TRUE OR FALSE?  Does it ever encode the ability to decode that mRNA?  What does that last question mean?
  • How do viruses achieve their remarkable adaptability with such small genomes?
  • What are the four key features used in classifying viruses?  Are these the best features? Could one do better?
  • What does (+) and (-) strand RNA mean?
  • What is the Baltimore system? What does it tell us?

Lecture 2 – The infectious cycle

  • What is a susceptible cell? A resistant cell? A permissive cell? Which describe the only cell that can take up a virus particle and replicate it?
  • Before the advent of cell culture, how were viruses propagated?
  • What is the difference between primary cells, cell lines, and diploid cell strains?
  • Name one famous immortal cell line.
  • What is cytopathic effect? Name two examples.
  • How does a plaque assay work? How many viruses are needed to form a plaque?
  • Are all virus particles infectious?  How would we know?  What is the term used by virologists to define this phenomenon?
  • What are the individual phases of the one step growth cycle, and what occurs during each?
  • How does a viral growth differ from bacterial growth?
  • What is MOI?
  • Do you believe this? At an MOI of 1, a significant number of cells will see no virions and a similar number will get one virion. Some (a smaller number) will get 2, 3, or more.  How do you know?
  • The numbers can be calculated using the Poisson distribution.  Try your hand: fill out the following table. Remember:

P(k)=e-mmk/k!

P(k) is the fraction of cells infected by k virus particles, m is the moi.

Also  P0 = e-m

P0= probability of a cell not being infected

moi_Table

  • In addition to the plaque assay, what other ways are used to measure virus particles? Describe at least one.
  • What’s the big deal about green fluorescent protein? Who is Marty Chalfie anyway?
  • What’s the problem with Koch’s postulates these days?

Lecture 3 – Genomes and genetics

  • What information is or is not encoded in a viral genome?
  • The genome inside a virion is always a nucleic acid. If you could get it into a cell, would it start the replication cycle? YES, NO, MAYBE?
  • What are the only viral genome structures that have been identified?  There are less than 8 and more than 6.
  • Can you imagine a viral genome in a virion that never actually replicates?
  • Pick one of the algorithms for a virus replication strategy from chapter 3 and explain it.
  • What can viruses with segmented genomes do that other viruses with unimolecular genomes cannot?
  • Try to explain the ambisense strategy. Will this concept work for a DNA virus?
  • What is wild-type?
  • What is the name of the process by which viral DNA is introduced into cells? What about non-viral DNA?
  • There is an infectious DNA clone for at least one member of nearly every virus family. Why is this so important?

Lecture 4: Structure of viruses

  • What are the functions of virion proteins?
  • Racaniello said capsids are metastable.  What was he talking about?
  • He also said virions can be active containers. What does that mean?
  • Know the difference between capsid, nucleocapsid, envelope, and virion
  • How big are viruses compared with an alpha helix and a ribosome?
  • What are the two rules of symmetry that instruct how virions self assemble?
  • Helical virions often have precise lengths. How can this be?
  • Helical virions always have the nucleic acid inside the helical structure.  How can this be?
  • An icosahedron has three characteristics (these are invariable). What are they?
  • What does the T number describe?
  • How is the simplest icosahedral virion constructed?
  • If capsid proteins are not larger than 20-60 kDa, how do you make larger virions?
  • What is quasiequivalence?
  • What is a complex virion?  Why would evolution come up with such structures?
  • What is the function of viral envelope proteins?
  • What is the difference between a structured and an unstructured envelope?

Lecture 5 – Attachment and entry

  • Virions attach to cells.  What are the steps? Why is it sequential? Why is it dynamic? What steps are reversible?
  • What are the functions of cell receptors for viruses? Why must viruses attach to receptors to enter cells?
  • How does an icosahedral virion attach to cell receptors? An enveloped virion?
  • Why are two receptors sometimes required for entry into a cell?
  • How does a virion deliver the genome payload? A naked capsid, an enveloped virion must be different. Yes, No, Maybe?
  • Why must membrane fusion be regulated? How is it regulated?
  • How does the viral genome behave after the virion uncoats?  Obviously the different genome types end up in different places inside the cell. How could this happen?  Diffusion plays a role, yes or no?
  • Are all viral nucleic acids released from the capsid/nucleocapsid during entry?
  • What is the role of the cellular cytoskeleton in virus entry?
  • Most DNA viral genomes must enter the nucleus. How is this done?

Lecture 6 – RNA-directed RNA synthesis

  • What are the two requirements for copying RNA viral genomes?
  • Why must (-) strand viral RNA be coated with protein in the virion? Why not (+) strand viral genomes? Are there exceptions?
  • What structural features are common to all nucleic acid polymerases?
  • All RNA viruses encode their own replication system. True or False?  Why?
  • It is amazing that RNA viral genomes can replicate. Do you agree with this statement? Why or why not?
  • If you discovered a previously unknown RNA virus, what would be the best guess about its genome topology: linear, circular, double stranded, single stranded?  Why?
  • How do viral RNA genomes work? Compare +, -, and ds RNA genomes
  • How do they encode information? Compare +, -, and ds RNA genomes
  • How is this information used to “operate” an infectious cycle? What must happen first when one of these RNA genomes enters a cell?  Or, put another way, where’s the polymerase?
  • In the (–) sense RNA genomes, the (+) strands and mRNA are the same. True or False? Why or why not?
  • Consider a (+) sense ssRNA genome. What is the difference between the viral mRNA and the (-) strand complement of the genome?
  • What is the primer for picornavirus replication?
  • Compare the monopartite strategy with the segmented genome strategy for minus strand ssRNA genomes.
  • When the genome of a negative sense ssRNA virus is purified and introduced into cells that are permissive to the original intact virus, what will happen?  Why?  If you did this same experiment with a plus-sense ssRNA virus, what would happen?
  • How is poly(A) added to mRNAs of RNA viruses?
  • Influenza virus will NOT GROW in a cell from which the nucleus has been removed. Why is that? It is an RNA virus.
  • What is” cap snatching” and why is it necessary for influenza replication?
  • Influenza virus replicates in the nucleus of cells and therefore does not require a viral polymerase to replicate its genome.  True or False? Why?
  • Why is viral RNA synthesis a source of diversity?
  • What is RNA editing? What good is it?

Lecture 7 – Reverse transcription and integration

  • Remember I asked you before about the possibility of a viral genome that never replicates?  That would be the retrovirus genomes. What is their remarkable strategy?
  • What are the unique viral enzymes that are required to make more retroviral genomes? What do they do? What is the origin of the name of the enzyme?
  • What does this statement mean?  Retroviral genomes are diploid.  What good is this property?
  • What is a provirus?  How many proviral copies are produced after a retrovirus infection?
  • Take a shot at explaining how reverse transcription works. For example, what are the primers for the polymerase? What are the three kinds of biochemical reactions catalyzed by reverse transcriptase?
  • What are the functions of RNAse H and integrase during retroviral replication?
  • Which enzyme produces viral mRNAs in a cell infected with a retrovirus? Where is the promoter for mRNA synthesis?
  • If you expose polio virions and retroviral virions to UV radiation, the amazing fact is that retroviral virions are orders of magnitude more resistant to UV. Why is this so?  It has nothing to do with the fact that retrovirus virions are enveloped!
  • Both hepadnaviruses and retroviruses use reverse transcriptase to replicate, yet the retroviral virion has a (+) ssRNA inside while the hepadnaviral virion has a gapped dsDNA molecule inside. What’s that all about?
  • Does the hepadnavirus genome encode an RNAse H? An integrase? Why or why not?
  • Someone suggested that hepadnaviruses evolved from an ancestral retrovirus. What do you think of this idea?
  • Half of your DNA is made of mobile genetic elements. What does this mean?

Lecture 8 – Translation

  • What is the function of the 5’-cap on mRNAs?
  • How is translation from an IRES different from cap-dependent translation? Why are there IRESes?
  • Does poliovirus require cap-dependent translation for expression of its viral gene products?
  • Does initiation of translation always begin with a methionine?
  • How do viruses get around the ‘one mRNA, one protein’ limitation of the eukaryotic translation apparatus?
  • What is “leaky” in the leaky scanning model?
  • What is an eIF2a kinase and what does it do? How do viruses get around it?
  • How does cleavage of eIF4G interfere with translation? Why does this occur in virus infected cells?

Lecture 9 – Genome replication of DNA viruses

  • What are the different topologies of DNA viral genomes? How are the DNAs replicated?
  • Where in the cell do DNA viruses replicate?
  • Why is viral DNA replication always delayed after infection?
  • What are the two possible outcomes of viral DNA replication?
  • What are the minimal requirements for DNA replication?
  • Do DNA viral genomes always encode their own DNA polymerase?  If not, where does the polymerase come from?
  • What viral proteins are involved in DNA replication?
  • What is a viral origin of replication? How do they work?
  • What are the two basic modes of DNA replication?
  • What is the function of polyomavirus T antigen?
  • Do DNA genomes exist that do not require a DNA polymerase to copy them?
  • What is bidirectional replication? Does it happen on all DNA viral genomes?
  • Synthesis of the leading DNA strand is easy. Why is synthesis of the lagging strand difficult?
  • What events occur after a polyomavirus DNA genome is replicated?
  • Explain how the hepadnaviral DNA genome can replicate. That genome as it comes from the virion is a mess!
  • Silverstein said that ‘adenoviral DNA replication is semiconservative and assymetric’. What does he mean by that statement?
  • All DNA viruses must replicate in the nucleus. True or False?
  • What is a primer? What is the function?  What kinds of primers are there?
  • There is one DNA virus family that encodes its own entire replication and transcription system. Which one?  Why does it do this?
  • How might a herpes simplex virus genome generate four isomers?
  • What happens to genes encoded within the repeat regions of herpes virus DNA when the inversions occur?

Lecture 10 – Transcription and RNA processing

  • What is transcription? What are the generic steps in this process?
  • What happens to RNA transcripts?
  • What are the different possible fates of viral mRNAs?
  • What are the steps in the transcription of pre-mRNA?
  • Which control elements regulate mRNA synthesis?
  • What are the steps in initiation of mRNA synthesis?
  • Which virus was instrumental in the discovery of splicing? What is the purpose of splicing?
  • How does an enhancer work?
  • Host or viral proteins may regulate transcription. How do they function?
  • Describe positive autoregulatory and cascade regulation.
  • What is a transcriptional cascade and why is it necessary?
  • A primary transcript does not become a mRNA until it is exported. True or False.
  • HIV infected cells export unspliced and incompletely spliced mRNA molecules from the nucleus to the cytoplasm. Mammalian cells, however, do not normally export incompletely spliced mRNA molecules. How do viruses overcome this obstacle?
  • What’s a Charon and can you get to hell if you don’t know?

Lecture 11 – Assembly

  • True or false: the overall virion assembly process must be irreversible.
  • Why must viral proteins achieve high concentrations in the cell? How is this achieved?
  • How do viral structural proteins go to the ‘right place’ in the cell?
  • True or false: the virion structure is at an energy minimum.  Why or why not?  Certainly, it must be very stable because it has to survive in the environment outside the infected host.
  • What features or motifs are found on integral membrane proteins that are necessary for them to function in the plasma membrane?
  • How do virion components achieve high concentrations for efficient assembly?
  • What is a sub-assembly? Provide an example.
  • Distinguish between assisted assembly and self-assembly.
  • We distinguished between sequential and concerted assembly. How do these processes differ?
  • How does the viral nucleic acid get packaged into a virion? How is the viral genome distinguished from other nucleic acids in the cell?
  • Egress of a retrovirus and a herpesvirus are remarkably different even though they both are enveloped viruses. Where does the envelope for each virus originate?
  • How does an L domain participate in viral budding?
  • Most viruses leave cells by one of which two general mechanisms?
  • What is the advantage of cell-cell spread over release of particles?
  • Can you imagine targeted egress or release of virions from infected cells? That is, virions emerge from a specific place and not all over a cell.  What advantage would this process provide for infection of an epithelial cell or a neuron?
Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 0 comments }

TWiV 72: Bucket of bolts

by Vincent Racaniello on 7 March 2010

Hosts: Vincent Racaniello, Dickson Despommier, Alan Dove, and Rich Condit

This week the TWiV team explains CRISPR/Cas, the immune system of bacteria and archaea, how novel viruses are discovered by deep sequencing of small RNAs, and the relationship between dry weather and outbreaks of West Nile virus infection.

This episode is sponsored by Data Robotics Inc. Use the promotion code VINCENT to receive $50 off a Drobo or $100 off a Drobo S.

Win a free Drobo S! Contest rules here.

Audio clip: Adobe Flash Player (version 9 or above) is required to play this audio clip. Download the latest version here. You also need to have JavaScript enabled in your browser.

Download TWiV #72 (62 MB .mp3, 85 minutes)

Subscribe to TWiV (free) in iTunes , at the Zune Marketplace, by the RSS feed, or by email.

Links for this episode:

Weekly Science Picks

Dickson Scientist as Chef by Dickson Despommier (pdf)
Alan Networked Organisms and Habitats (NOAH) iPhone app
Rich Never Cry Wolf by Farley Mowat
Vincent The Dish

Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv or leave voicemail at Skype: twivpodcast. You can also post articles that you would like us to discuss at microbeworld.org and tag them with twiv.

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 0 comments }

Cutting the cold chain

by Vincent Racaniello on 4 March 2010

hydrisNo matter what advanced method is used to develop and produce vaccines, their efficacy is limited by old technology – the refrigerator. All viral vaccines must either be stored frozen, or kept at low temperatures. If they are not properly stored, they lose potency and do not confer protection against infection. The decay of vaccine potency is a particular problem in underdeveloped regions that lack a continuous network of stable, refrigerated storage facilities – the ‘cold chain’. To solve this problem, the World Health Organization developed a portable kerosene-fired freezer to maintain the potency of oral poliovirus vaccine. A new method for drying vaccines could radically change the dependency of vaccines on the cold chain.

The effect of elevated temperature on viral viability is clear: after one week at 37°C in a buffered solution, adenovirus vaccine vectors lose all infectivity and cannot stimulate immune responses. Poxvirus vaccine vectors endure up to 1 month at 37°C or 45°C but then lose effectiveness.

An important component of the new vaccine preservation technique is the ability of the non-reducing disaccharides trehalose and sucrose to form a solid in which no chemical reactions occur. Because of this property, these sugars are often used as stabilizing agents for biological products.

Adenovirions and poxvirions were placed in suspensions of a mixture of trehalose and sucrose and slowly dried onto filters at ambient temperatures. The sugars formed an ultrathin glass on the membrane in which the virions were suspended. In this form the viruses could be stored for up to 6 months at 45°C with no loss of infectivity of immunogenicity.

The ability to preserve viral vaccines on a small filter also allows simple administration of the vaccine. The virus-containing filter is placed into a plastic holder which can be fitted between a conventional syringe and needle. As buffer is forced through the filter, the vaccine-containing glass dissolves and flows into the needle for injection.

There are many questions that must be answered before this technology can be put into general use. It remains to be determined whether glass-embedded vaccines will be stable when subjected to extreme temperature fluctuations encountered during shipment. Furthermore, the method of preservation must be shown to work for currently used vaccines, such as those for polio.

The oral poliovaccine was once given to children on cubes of sugar. Embedding viruses in sugar may soon allow less costly and more effective global delivery of disease-preventing vaccines.

Alcock, R., Cottingham, M., Rollier, C., Furze, J., De Costa, S., Hanlon, M., Spencer, A., Honeycutt, J., Wyllie, D., Gilbert, S., Bregu, M., & Hill, A. (2010). Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass Science Translational Medicine, 2 (19), 19-19 DOI: 10.1126/scitranslmed.3000490

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 0 comments }

Virology lecture #11: Assembly

by Vincent Racaniello on 1 March 2010


Download: .wmv (354 MB) | .mp4 (104 MB)

Visit the virology W3310 home page for a complete list of course resources.

Share this post:
  • TwitThis
  • Digg
  • del.icio.us
  • Facebook
  • Google Bookmarks
  • StumbleUpon

{ 2 comments }